Prolonged survival of mice with Pseudomonas aeruginosa-induced sepsis by rIL-12 modulation of IL-10 and interferon-γ

Journal of Medical Microbiology

Volumn 49, Issue 8, 2000, Pages 701-707

  Yamaguchi, T ^a   Hirakata, Y ^a   Izumikawa, K ^a   Miyazaki, Y ^a   Maesaki, S ^a   Tomono, K ^a   Yamada, Y ^a   Kohno, S ^a   Kamihira, S ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 12; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SIMULATION; GRAM NEGATIVE INFECTION; IMMUNOMODULATION; INFLAMMATION; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; SEPTICEMIA; SURVIVAL;

EID: 0033887033     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-49-8-701     Document Type: Article

References (43)

1. Gram-negative pathogens in septicaemic infections
2. Mortality rates amongst mice with endogenous septicaemia caused by Pseudomonas aeruginosa isolates from various clinical sources
3. Influence of various immunosuppressive agents on the occurence of endogenous bacteraemia in mice
4. Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice
5. Time course of cytokine levels in sepsis
6. Inflammatory mediators and their influence on haemostasis
7. Role of tumor necrosis factor-alpha in disease states and inflammation
8. Interleukin 10 protects mice from lethal endotoxemia
9. Immunosuppressive and anti-inflammatory properties of interleukin 10
10. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock
11. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13
12. Monocyte deactivation - Rationale for a new therapeutic strategy in sepsis
13. Regulation of human cytolytic lymphocyte responses by interleukin-12
14. Differential effects of interleukin-12 on the development of naive mouse CD4+ T cells
15. Cytokine treatment of central nervous system infection: Efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis
16. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection
17. Recombinant interleukin 12 cures mice infected with Leishmania major
18. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans
19. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism
20. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma
21. Role of interleukin 12 in experimental neonatal sepsis caused by group B streptococci
22. Chromosomal genetics of Pseudomonas
23. The contribution of exoproducts to virulence of Pseudomonas aeruginosa
24. Role of bacterial association with Kupffer cells in occurrence of endogenous systemic bacteremia
25. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome
26. Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection
27. Interleukin-1 receptor antagonist
28. Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice
29. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group
30. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group
31. Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis
32. Comparison of the interleukin-6 and interleukin-10 response in children after severe traumatic brain injury or septic shock
33. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation
34. Bacterially preexposed T cells impair bacterial elimination by non-Th1/Th2 cell mechanisms in a model of intra-abdominal infection
35. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice
36. Adverse effects of tumour necrosis factor in cyclophosphamide-treated mice subjected to gut-derived Pseudomonas aeruginosa sepsis
37. Enhancement of antibody-dependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12
38. Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis
39. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia
40. Protection of mice from group A streptococcal skin infection by interleukin-12